Sign In

A subscription to JoVE is required to view this content. Sign in or start your free trial.

In This Article

  • Summary
  • Abstract
  • Introduction
  • Protocol
  • Representative Results
  • Discussion
  • Acknowledgements
  • Materials
  • References
  • Reprints and Permissions

Summary

Experimental autoimmune encephalomyelitis is one of the most widely used murine models of multiple sclerosis. In the current protocol, C57BL/6J mice of both sexes are immunized with myelin oligodendrocyte glycoprotein peptide, resulting mainly in ascending paresis of the tail and limbs. Here we discuss the protocol of EAE induction and evaluation.

Abstract

Multiple Sclerosis (MS) is a chronic autoimmune inflammatory disease affecting the central nervous system (CNS). It is characterized by different prevalence in the sexes, affecting more women than men, and different outcomes, showing more aggressive forms in men than in women. Furthermore, MS is highly heterogeneous in terms of clinical aspects, radiological, and pathological features. Thus, it is necessary to take advantage of experimental animal models that allow the investigation of as many aspects of the pathology as possible. Experimental autoimmune encephalomyelitis (EAE) represents one of the most used models of MS in mice, modeling different disease features, from the activation of the immune system to CNS damage. Here we describe a protocol for the induction of EAE in both male and female C57BL/6J mice using myelin oligodendrocyte glycoprotein peptide 35-55 (MOG35-55) immunization, which leads to the development of a chronic form of the disease. We also report the evaluation of the daily clinical score and motor performance of these mice for 28 days post immunization (28 dpi). Lastly, we illustrate some basic histological analysis at the CNS level, focusing on the spinal cord as the primary site of disease-induced damage.

Introduction

Multiple Sclerosis (MS) is a chronic autoimmune inflammatory disease affecting the central nervous system (CNS). It shows the presence of perivascular infiltration of inflammatory cells, demyelination, axonal loss, and gliosis1. Its etiology remains unknown, and its clinical aspects, radiographic, and pathological features suggest remarkable heterogeneity in the disease2.

Due to its unknown etiology and complexity, at present, no animal model recapitulates all the clinical and radiological features displayed in human MS3,4. However, va....

Protocol

The animal care and handling in the present work was performed according to the European Union Council Directive of 22nd September 2010 (2010/63/UE); all the procedures reported in the present study were approved by the Italian Ministry of Health (407/2018-PR) and by the Ethical Committee of the University of Torino (Project n° 360384). We suggest conforming to the experimental design to the ARRIVE guidelines originally published by Kilkenny et al. in 201020. Before starting, ensur.......

Representative Results

EAE follow-up after immunization
This was assessed as described below.

Body weight and food intake
The two-way analysis of variance (ANOVA) (sex and time as independent variables) shows a decrease in the BW of EAE animals of both sexes, especially within the second week post induction (F(1,57) = 4.952, p < 0.001; Figure 2A). However, the sexual dimorphism in BW is always maintained (

Discussion

The MOG35-55-induced EAE protocol that we described led to the development of a chronic form of MS in C57BL/6J mice7,8,13. In these representative results, we reported that the animals of both sexes that underwent the immunization procedure developed a chronic form of the disease (i.e., they do not fully recover after the disease onset, they accumulate deficits, and maintain a CS at least of 1.5 in the chronic phase)........

Acknowledgements

This work has been supported by Ministero dell'Istruzione, dell'Università e della Ricerca - MIUR project Dipartimenti di Eccellenza 2018-2022 and 2023-2027 to Department of Neuroscience Rita Levi Montalcini; Cavalieri-Ottolenghi Foundation, Orbassano, Italy. BB was fellow of INFRA-P, Piedmont Region (n.378-35) (2022-2023) and PRIN 2020 - 20203AMKTW. We thank Fondazione per la Ricerca Biomedica Onlus (FORB) for the support. The publication fees have been supported by the kind donation of Distretto Rotaract 2031, and particularly, Rotaract Club Torino Nord-Est. We thank Elaine Miller for the proofreading of our manuscript.

....

Materials

NameCompanyCatalog NumberComments
18 G x 1 ½“ 1.2 x 40 mm needle for the glass syringe TerumoTER-HYP-18G-112-PIN
Digital camera connected to the optical microscopeNIKON DS-U1 digital camera
Electronic precision balanceMerckMod. Kern-440-47N, resolution 0.1 g
Eosin YSigma-AldrichHT110216
Glass syringe pipet “ultra asept” 10 mlSacco System L003465
Glassware (i.e., becker to prepare the emulsion)VWR213-1170, 213-1172
Hematoxylin (Mayer’s)Sigma-AldrichMHS32Filter before using it. 
Image analysis SoftwareFiji
Incomplete Freund’s adjuvant (IFA)Sigma-AldrichF5506Store at +4 °C. 
IsofluraneWellona PharmaThis drug is used as inhalational anaesthetic.
Male and female C57BL/6J miceJackson Laboratory, EnvigoAge 8-10 weeks, optimal body weight of ~20 g. 
MicrotomeLeica HistoCore BIOCUT R
Mounting Medium Merck107961
Mouse RotarodUgo Basile #47600
Mycobacterium tuberculosis (MT), strain H37Ra Difco Laboratories Inc. 231141Store at +4 °C.
Myelin oligodendrocyte glycoprotein peptide 35-55 (MOG35-55)EspikemEPK1Store at -80 °C diluted (2 mg/mL) in physiological solution; prepare it on the day of the immunization to avoid, as much as possible, alterations or contaminations. 
Optical microscopeNIKON eclipse 90i
Paraformaldehyde (PFA)Sigma-Aldrich158127Store at +4 °C once diluted (4%) in phosphate buffer. 
Pertussis toxin (PT)Duotech PT.181Store at -80°C diluted (concentration 5 µg/mL) in physiological solution 
Physiological solution (sodium chloride 0.9% solution)B. EurospitalA 032182038Store at +4 °C once opened.
Saline phosphate buffer (PBS)Thermo ScientificJ61196.AP
Software for image acquisition NIS-Element AR 2.10
Syringes U-100 0.5 mL with 30 G x 5/16” (0.30 x 8 mm) in fixed needle NiproSYMS-0.5U100-3008B-EC
Syringes U-100 1 mL with 26G x ½” (0.45 x 12.7 mm) in needlePIC20,71,26,03,00,354
Vet ointment for eyesLacrilube, Lacrigel Europhta
XylazineRompunThis mixture of drug is used as injectable anaesthetic and sedative. 
Zolazepam and TiletamineZoletil  100This drug is used as injectable anaesthetic, sedative, muscle relaxer, and analgesic

References

  1. Thompson, A. J., Baranzini, S. E., Geurts, J., Hemmer, B., Ciccarelli, O. Multiple sclerosis. Lancet. 391 (10130), 1622-1636 (2018).
  2. Gold, S. M., Willing, A., Leypoldt, F., Paul, F., Friese, M. A. Sex differences in autoimmune disorders of the central nervous syst....

Explore More Articles

Multiple SclerosisExperimental Autoimmune EncephalomyelitisEAE ModelSex DifferencesMOG35 55Clinical AssessmentNeuroinflammationAutoimmune DiseaseCentral Nervous System

This article has been published

Video Coming Soon

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2024 MyJoVE Corporation. All rights reserved